The Adelaide-based biotechnology company, BresaGen, expects to receive human embryonic stem (ES) cells in the near future from the University of Wisconsin, USA. The cells are intended for use in the BresaGen Cell Therapy Programme which is conducted in the Department of Biochemistry at Adelaide University under the scientific direction of Professor Peter Rathjen.
The above story is based on materials provided by Adelaide University. Note: Materials may be edited for content and length.
Cite This Page:
Adelaide University. "Biotechnology Research To Grow From Embryonic Start." ScienceDaily. ScienceDaily, 15 September 2000. <www.sciencedaily.com/releases/2000/09/000905211456.htm>.
Adelaide University. (2000, September 15). Biotechnology Research To Grow From Embryonic Start. ScienceDaily. Retrieved April 16, 2014 from www.sciencedaily.com/releases/2000/09/000905211456.htm
Adelaide University. "Biotechnology Research To Grow From Embryonic Start." ScienceDaily. www.sciencedaily.com/releases/2000/09/000905211456.htm (accessed April 16, 2014).